Dr. Lea Baer, MD - Stony Brook, NY ...

Dr. Lea Baer, MD

Claim this profile

Stony Brook University Medical Center

Studies Breast Cancer
Studies Breast cancer
8 reported clinical trials
23 drugs studied

Area of expertise

1

Breast Cancer

Lea Baer, MD has run 8 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
ER negative
PR negative
2

Breast Cancer

Lea Baer, MD has run 6 trials for Breast cancer. Some of their research focus areas include:

HER2 positive
ER negative
PR negative

Affiliated Hospitals

Image of trial facility.

Stony Brook University Medical Center

Image of trial facility.

Stony Brook Cancer Center

Clinical Trials Lea Baer, MD is currently running

Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Recruiting

2 awards

Phase 3

47 criteria

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

More about Lea Baer, MD

Clinical Trial Related

10 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Lea Baer, MD has experience with

  • Paclitaxel
  • Carboplatin
  • Cyclophosphamide
  • Pembrolizumab
  • Biospecimen Collection
  • Ribociclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Lea Baer, MD specialize in?

Is Lea Baer, MD currently recruiting for clinical trials?

Are there any treatments that Lea Baer, MD has studied deeply?

What is the best way to schedule an appointment with Lea Baer, MD?

What is the office address of Lea Baer, MD?

Is there any support for travel costs?